Viracta Therapeutics (NASDAQ:VIRX) Stock Rating Lowered by SVB Leerink

SVB Leerink cut shares of Viracta Therapeutics (NASDAQ:VIRX) from an outperform rating to a market perform rating in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has $3.00 price target on the stock, down from their prior price target of $5.00.

Other analysts have also issued research reports about the stock. Oppenheimer reduced their price target on shares of Viracta Therapeutics from $13.00 to $11.00 and set an outperform rating on the stock in a research report on Thursday, May 23rd. Royal Bank of Canada reduced their target price on Viracta Therapeutics from $6.00 to $4.00 and set an outperform rating on the stock in a report on Thursday.

Viracta Therapeutics Stock Down 11.8 %

VIRX opened at $0.31 on Friday. The stock has a market capitalization of $12.08 million, a price-to-earnings ratio of -0.25 and a beta of 0.73. Viracta Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.52. The company has a 50-day simple moving average of $0.52 and a 200 day simple moving average of $0.72.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.